The FY2025 (Dec) proxy of Vir Biotechnology names 17 peer companies for pay. Among Vir Biotechnology and these peers, CEO pay was 3rd highest of 7 and total shareholder return was 2nd highest of 7.
3rd highest of 7in Vir Biotechnology and its pay peers, FY2025 (Dec) by CEO pay:
$4.6M$11.4M
2nd highest of 7in Vir Biotechnology and its pay peers, FY2025 (Dec) by total shareholder return:
$6$34
Pay peer group, FY2025 (Dec) proxy
| Ultragenyx Pharmaceutical | ||
| Novavax | ||
| Beam Therapeutics | ||
| Intellia Therapeutics | ||
| Denali Therapeutics | ||
| Relay Therapeutics | ||
| Allogene Therapeutics, Inc. | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Dynavax Technologies | Not disclosed | Not disclosed |
| Editas Medicine Inc. | Not disclosed | Not disclosed |
| IGM Biosciences | Not disclosed | Not disclosed |
| Iovance Biotherapeutics | Not disclosed | Not disclosed |
| Janux Therapeutics | Not disclosed | Not disclosed |
| REGENXBIO Inc. | Not disclosed | Not disclosed |
| Replimmune Group | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
| iTeos Therapeutics | Not disclosed | Not disclosed |
'%20d='M450.888,318.933h6.906v.949h-2.9v7.592H453.84v-7.592h-2.953Zm15.185,3.691h-4.9v-3.691h-1.054v8.541h1.054v-3.849h4.9v3.849h1.054v-8.541h-1.054Zm5.431,1h4.745v-1H471.5v-2.689h4.956v-1h-6.01v8.594h6.221v-1H471.5Zm12.285.686,2.794,3.163h-1.318l-2.689-3.058H480.52v3.058h-1.055v-8.541h3.9a2.671,2.671,0,0,1,2.9,2.742A2.462,2.462,0,0,1,483.789,324.311Zm-.527-.79a1.727,1.727,0,0,0,1.845-1.793,1.753,1.753,0,0,0-1.845-1.793h-2.795v3.585Zm9.965-4.587,3.848,8.541h-1.16l-.843-1.9h-4.9l-.844,1.9h-1.16l3.849-8.541Zm1.476,5.694-2.057-4.588-2,4.588Zm8.647.105H500.5v2.742h-1.055v-8.541h3.9A2.9,2.9,0,1,1,503.349,324.733Zm0-4.8H500.5v3.8h2.847A1.9,1.9,0,0,0,503.349,319.936Zm6.538,3.69h4.745v-1h-4.745v-2.689h4.956v-1h-6.011v8.594h6.222v-1h-5.167Zm13.813.475a2.455,2.455,0,1,1-4.9,0v-5.115h-1.054V324.1a3.481,3.481,0,1,0,6.96,0v-5.115h-1Zm3.27-4.218h2.953v7.592h1.054v-7.592h2.9v-.949H526.97Zm9.28,7.592H537.3v-8.541H536.25Zm8.277-.844a3.2,3.2,0,0,1-3.374-3.374,3.161,3.161,0,0,1,3.374-3.427,3.393,3.393,0,0,1,2.372.949l.738-.686a4.343,4.343,0,0,0-3.11-1.265,4.227,4.227,0,0,0-4.429,4.428,4.158,4.158,0,0,0,4.429,4.377,4.465,4.465,0,0,0,3.164-1.265l-.738-.738A3.346,3.346,0,0,1,544.527,326.63Zm8.7-4.007c-1.266-.211-2.32-.474-2.32-1.423,0-1.055,1.16-1.476,2.267-1.476a2.761,2.761,0,0,1,2.32,1l.791-.474a3.344,3.344,0,0,0-3.217-1.53c-1.476,0-3.269.58-3.269,2.373,0,1.74,1.635,2.109,3.269,2.372,1.318.211,2.479.527,2.479,1.582,0,1.266-1.371,1.582-2.426,1.582a3.067,3.067,0,0,1-2.742-1.476l-.9.527a3.7,3.7,0,0,0,3.639,2c1.634,0,3.48-.633,3.48-2.531S554.914,322.887,553.227,322.623Zm-90.16-9.121h-12.18V285.611h12.18c5.062,0,9.333,2.531,9.333,7.8a6.1,6.1,0,0,1-4.114,5.747,6.942,6.942,0,0,1,5.01,6.643C473.3,311.71,468.34,313.5,463.068,313.5Zm-8.7-15.923h8.858c3.322,0,5.747-1.212,5.747-4.112,0-3.11-2.531-4.692-5.905-4.692h-8.7Zm0,12.6h8.7c2.9,0,6.749-.738,6.749-4.534-.053-3.48-3.585-4.956-6.591-4.956h-8.858Zm32.426,3.638c-6.063,0-10.334-4.007-10.334-10.281a9.833,9.833,0,0,1,10.176-10.176c6.011,0,10.6,3.691,9.807,11.547H479.729c.369,3.638,3.321,5.905,7.117,5.905,2.215,0,4.956-.9,6.222-2.479l2.215,2C493.279,312.711,489.851,313.819,486.793,313.819Zm-7.012-11.652,13.6.053c-.159-3.8-2.794-5.905-6.643-5.905A6.7,6.7,0,0,0,479.781,302.167Zm40.6,11.336h-3.163l-.052.053-.105-3.585a8.3,8.3,0,0,1-7.223,3.955c-5.642,0-10.071-3.9-10.071-10.282s4.481-10.176,10.123-10.123a8.247,8.247,0,0,1,7.276,3.9l.052-3.585h3.163Zm-10.386-16.924a7.2,7.2,0,0,0,0,14.394C519.483,310.972,519.483,296.578,509.993,296.578Zm43.34,5.694V313.45H556.6V302.219c0-5.378-3.11-8.752-8.277-8.752a7.315,7.315,0,0,0-6.908,4.271c-1.107-3.111-3.9-4.271-6.59-4.271a6.3,6.3,0,0,0-5.8,3.217l-.211-2.847H525.81L525.7,313.45h3.269V302.325c0-3.216,2.109-5.747,5.325-5.747,3.268,0,5.273,2.531,5.273,5.747V313.45h3.269V302.325c0-3.216,2.161-5.747,5.378-5.747C551.488,296.578,553.333,299.056,553.333,302.272ZM450.308,269.056a25.12,25.12,0,0,0-3.48,1.371l4.534,6.221Zm-14.5,10.6,7.012,3.27-4.587-6.169A32.115,32.115,0,0,0,435.808,279.653Zm1.423-7.54,10.809,8.911-5.273-12.917A52.977,52.977,0,0,0,437.232,272.113Zm48.93,13.6a25.049,25.049,0,0,0-1.634-3.374l-5.958,4.9ZM431.274,289.3a29.46,29.46,0,0,0-.738,3.744l7.8-.475Zm2.689-6.7a28.869,28.869,0,0,0-1.635,3.427l7.645,1.424Zm40.6-10.6-2.794,7.118,5.853-4.956A24.584,24.584,0,0,0,474.561,272.008Zm-17.135-4.323c-1.266.106-2.479.263-3.691.475l2.794,7.117ZM467.971,269l-.949,7.592,4.429-6.222A19.889,19.889,0,0,0,467.971,269Zm-37.646,27.522a30.9,30.9,0,0,0,.211,3.849l7.487-2.479Zm52.251-17.083a30.79,30.79,0,0,0-2.426-2.9l-4.481,6.222Zm-51.355,24.306a30.261,30.261,0,0,0,1.213,3.691l6.643-4.27ZM464.6,268.16c-.633-.105-1.213-.212-1.846-.264s-1.265-.105-1.845-.158l.949,7.539Zm-28.63,45.607,5.378-5.8-7.486,2.531A26.612,26.612,0,0,0,435.966,313.766Z'%20transform='translate(-430.325%20-267.685)'%20fill='%23fff'/%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
17 companies
Changes by year
FY2024 (Dec) proxy
- RemovedBiohaven Pharmaceuticalspay peer groupFor the 2024 peer group, the Compensation Committee made no changes relative to the group in 2023 other than removing three peers that had been acquired during the prior year (Biohaven Pharmaceuticals, Turning Point Therapeutics, and Global Blood Therapeutics)
- RemovedGlobal Blood Therapeuticspay peer groupFor the 2024 peer group, the Compensation Committee made no changes relative to the group in 2023 other than removing three peers that had been acquired during the prior year (Biohaven Pharmaceuticals, Turning Point Therapeutics, and Global Blood Therapeutics)
- RemovedTurning Point Therapeuticspay peer groupFor the 2024 peer group, the Compensation Committee made no changes relative to the group in 2023 other than removing three peers that had been acquired during the prior year (Biohaven Pharmaceuticals, Turning Point Therapeutics, and Global Blood Therapeutics)
FY2023 (Dec) proxy
- AddedDynavax Technologiespay peer groupThe Committee added Apellis Pharmaceuticals, Inc. and Dynavax Technologies Corporation based on their current respective market values, therapeutic similarities to Vir, and their respective stages of development
- RemovedAcceleron Pharma Inc.pay peer groupdue to its acquisition by Merck & Co., Inc
- RemovedAllakos Inc.pay peer groupdue to its acquisition by Merck & Co., Inc
- RemovedINOVIO Pharmaceuticals, Inc.pay peer groupdue to its acquisition by Merck & Co., Inc
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.